WE’RE ON A MISSION TO PREVENT AND EVEN REVERSE ALZHEIMER’S DISEASE (AD)
Our 30+ year commitment to addressing AD grows naturally from our
human health care
mission. It’s one of society’s greatest unmet medical needs, and we’re determined to find precision solutions that go beyond treatment, to prevention and reversal. To that end, we’ve amassed an unparalleled set of capabilities:
We’re the only company with programs targeting amyloid (the main component of plaques found in the brains of people with AD); tau (a protein that’s vital to brain health); neurodegeneration; inflammation; and the clinical symptoms of dementia, such as cognition and sleep-wake disorders.
Our rich pipeline includes a wide scope of investigational compounds and diagnostic methods being researched in AD. In addition, we’re exploring novel therapies designed to address clinical symptoms such as cognition and sleep disorders.
Eisai and Biogen are jointly researching disease-modifying compounds* for potential treatment of AD.
Our ground-breaking Center for Genetics Guided Dementia Discovery (G2D2) is focused on delivering a new generation of immunodementia drugs that can bolster the body’s immunity against dementia.
We’re proud to have dedicated more than 30 years to research, development and commercialization in our relentless pursuit of treatments for Alzheimer’s
disease and dementia.”
Chairman, Eisai Inc. Global President, Neurology Business Group